MX2008014004A - 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. - Google Patents

1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.

Info

Publication number
MX2008014004A
MX2008014004A MX2008014004A MX2008014004A MX2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A MX 2008014004 A MX2008014004 A MX 2008014004A
Authority
MX
Mexico
Prior art keywords
carboxamides
benzimidazole
substituted
parp inhibitors
potent parp
Prior art date
Application number
MX2008014004A
Other languages
English (en)
Inventor
Jianchun Gong
Virajkumar B Gandhi
Thomas D Penning
Sheela A Thomas
Vincent L Giranda
Gui-Dong Zhu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2008014004A publication Critical patent/MX2008014004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a 1H-benzimidazol-4-carboxamidas de la fórmula (I), su preparación, y su uso como inhibidores de la enzima poli(ADP-ribosa)polimerasa para la preparación de fármacos.
MX2008014004A 2006-05-02 2007-05-02 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. MX2008014004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79666306P 2006-05-02 2006-05-02
PCT/US2007/067991 WO2007131016A2 (en) 2006-05-02 2007-05-02 Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors

Publications (1)

Publication Number Publication Date
MX2008014004A true MX2008014004A (es) 2008-11-12

Family

ID=38668505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008014004A MX2008014004A (es) 2006-05-02 2007-05-02 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.

Country Status (9)

Country Link
US (2) US20070259937A1 (es)
EP (1) EP2012780B1 (es)
JP (1) JP5228237B2 (es)
CN (1) CN101511821B (es)
AT (1) ATE553104T1 (es)
CA (1) CA2647373C (es)
ES (1) ES2385849T3 (es)
MX (1) MX2008014004A (es)
WO (1) WO2007131016A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0200312A3 (en) 1998-11-03 2002-12-28 Basf Ag Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
ATE536349T1 (de) * 2005-09-29 2011-12-15 Abbott Lab In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ES2342007T3 (es) * 2005-11-15 2010-06-30 Abbott Laboratories 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp).
CA2647545C (en) * 2006-04-03 2016-02-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
KR101591656B1 (ko) * 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
MX337421B (es) * 2008-01-08 2016-03-04 Merck Sharp & Dohme Sales farmaceuticamente aceptables de 2-{4-[(3s)-piperidin-3-il]fe nil}-2h-indazol-7-carboxamida.
WO2010083199A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
WO2012096813A1 (en) * 2011-01-11 2012-07-19 Merck Sharp & Dohme Corp. Imidazole derivatives
CN103242273B (zh) * 2012-02-09 2015-06-03 中国科学院上海药物研究所 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN102627610B (zh) * 2012-04-11 2014-06-25 江苏先声药物研究有限公司 一类苯并咪唑类衍生物及其应用
MX348338B (es) 2012-10-15 2017-06-07 Albemarle Corp Procesos para la síntesis de 2-amino-4, 6-dimetoxibenzamida y otros compuestos de benzamida.
CN104003979B (zh) * 2013-02-21 2016-08-17 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪类化合物、其药物组合物及其制备方法和用途
CN104230896A (zh) * 2013-06-17 2014-12-24 上海汇伦生命科技有限公司 苯并咪唑-2-哌嗪杂环类化合物、其药物组合物及其制备方法和用途
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1354554A (en) 1970-08-31 1974-06-05 Robins Co Inc A H 2-substituted benzimidazoles
BE789679A (fr) * 1971-10-05 1973-04-04 Leo Pharm Prod Ltd Nouveaux derives d'acide amino-5 isophtalique et leurs procedesde preparation
US4093726A (en) * 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
DE3522230A1 (de) 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3830060A1 (de) 1988-09-03 1990-03-15 Boehringer Mannheim Gmbh 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel
PL324869A1 (en) 1995-08-02 1998-06-22 Univ Newcastle Ventures Ltd Benzimidazole compounds
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
US6184235B1 (en) 1996-08-14 2001-02-06 Warner-Lambert Company 2-phenyl benzimidazole derivatives as MCP-1 antagonists
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US6110903A (en) 1997-03-07 2000-08-29 Sankyo Company Ltd. Benzimidazole inhibitors of fructose 1,6-bisphosphatase
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
HUP0200312A3 (en) 1998-11-03 2002-12-28 Basf Ag Substituted 2-phenylbenzimidazoles, pharmaceutical compositions containing them, the production thereof and their use
KR20010080474A (ko) 1998-11-17 2001-08-22 스타르크, 카르크 2-페닐벤즈이미다졸 및 2-페닐인돌, 이들의 제법 및 용도
DK1133477T3 (da) * 1998-11-27 2004-06-21 Abbott Gmbh & Co Kg Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
DE19916460B4 (de) 1999-04-12 2006-12-21 Abbott Gmbh & Co. Kg Substituierte Benzimidazole, deren Herstellung und Anwendung
DE19918211A1 (de) * 1999-04-22 2000-10-26 Basf Ag Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
AU7314200A (en) 1999-09-17 2001-04-24 Yamanouchi Pharmaceutical Co., Ltd. Benzimidazole derivatives
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
DE10021468A1 (de) 2000-05-04 2001-11-08 Basf Ag Verwendung von PARP-Inhibitoren in kosmetischen Zubereitungen
WO2002068407A1 (fr) 2001-02-28 2002-09-06 Yamanouchi Pharmaceutical Co., Ltd. Compose benzimidazole
US7166292B2 (en) * 2001-06-29 2007-01-23 The Procter & Gamble Company Top-biased beneficial components on substrates
AU2002334355A1 (en) 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
EP1511744A4 (en) 2002-05-13 2009-10-21 Icagen Inc Bis-benzimidazoles and related compounds as potassium channel modulators
US20040034078A1 (en) 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
US20060084682A1 (en) 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
EP1590333A4 (en) 2003-01-23 2008-04-30 Crystalgenomics Inc GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
HU0301154D0 (en) 2003-04-28 2003-07-28 Hideg Kalman Dr Pharmaceutical composition
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
WO2006110683A1 (en) * 2005-04-11 2006-10-19 Abbott Laboratories 2-substituted-1h-benzimidazole-4-carboxamides are parp inhibitors
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
ATE536349T1 (de) * 2005-09-29 2011-12-15 Abbott Lab In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
ES2342007T3 (es) * 2005-11-15 2010-06-30 Abbott Laboratories 1h-benzimidazol-4-carboxamidas sustituidos eficaces como inhibidores de (parp).
US20090029966A1 (en) * 2006-01-17 2009-01-29 Abbott Laboratories Combination therapy with parp inhibitors
US20080293795A1 (en) * 2006-01-17 2008-11-27 Abbott Laboratories Combination therapy with parp inhibitors
US20080146638A1 (en) * 2006-01-17 2008-06-19 Abbott Laboratories Combination therapy with parp inhibitors
US20080280867A1 (en) * 2006-01-17 2008-11-13 Abbott Laboratories Combination therapy with parp inhibitors
DK2338487T3 (da) * 2006-01-17 2013-12-09 Abbvie Bahamas Ltd Kombinationsterapi med PARP-inhibitorer
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
US8067613B2 (en) * 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors

Also Published As

Publication number Publication date
CA2647373A1 (en) 2007-11-15
JP5228237B2 (ja) 2013-07-03
US7999117B2 (en) 2011-08-16
JP2009535427A (ja) 2009-10-01
EP2012780B1 (en) 2012-04-11
CN101511821A (zh) 2009-08-19
US20070259937A1 (en) 2007-11-08
ES2385849T3 (es) 2012-08-01
WO2007131016A2 (en) 2007-11-15
ATE553104T1 (de) 2012-04-15
US20090186877A1 (en) 2009-07-23
WO2007131016A3 (en) 2008-12-18
CN101511821B (zh) 2013-07-17
EP2012780A4 (en) 2009-06-24
EP2012780A2 (en) 2009-01-14
CA2647373C (en) 2014-03-18

Similar Documents

Publication Publication Date Title
MX2008014004A (es) 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
WO2007149907A3 (en) Pyrazoloquinazolinones as parp inhibitors
MY148634A (en) Pyridazinone derivatives
WO2007125103A3 (en) Benzamide glucokinase activators
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
WO2008049116A3 (en) Substituted indoles
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
ZA200807274B (en) Novel pyridine derivatives
WO2008145688A3 (en) Pyrrolopyridine compounds, process for their preparation, and their use as medicaments
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009156462A3 (en) Organic compounds
WO2007089768A3 (en) 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
JO2778B1 (en) Certain vehicles, installations and methods
TW200740814A (en) Compounds
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2009094457A3 (en) Substituted benzhydrylethers
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2010077730A3 (en) Indanone inhibitors of acetylcholinesterase
WO2008098143A3 (en) Antimicrobial compounds and methods of use
WO2010059639A3 (en) Hydroxyadamantyl inhibitors of dipeptidylpeptidase iv

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights